International Journal of Dental Sciences

Authors
Priyank Sudani, Dangar Shayam M, Isha Brahmbhatt, Khushbu Sanjay Raval, Anjali H Ghadia, Radhika J Kachhadiya

Abstract
Introduction: Formocresol has been a well-known pulpotomy medicament over many years. It is considered the “gold standard” pulpotomy agent in pediatric dentistry. However, concerns have been raised over its use in children. It has been reported that formocresol has toxic and mutagenic effects in cell culture, dental crypts, and precancerous epithelial cells. Therefore, additional biocompatible treatment alternatives are required to replace formocresol pulpotomy. Aim: To evaluate and compare formocresol mineral trioxide aggregate (MTA) as pulpotomy medicaments by clinical and radiographic assessments in primary molar. Materials and Methods: This study was performed on 50 mandibular deciduous molar teeth requiring pulpotomy treatment. Children between age four and six years were randomly selected and divided into formocresol or MTA group. The patients were recalled after 3, 6 months respectively and evaluated clinically and radiographically. Results: Statistical analysis showed no significant difference between the two groups (P > 0.05). The overall clinical success of FC and MTA was 100 at 3, 6 follow-up. The overall radiographic success of FC was 100%, 96, and that of MTA was 100% at 3, 6 months, respectively. Conclusion: Mineral trioxide aggregate showed clinical and radiographic success as a dressing material following pulpotomy procedure in primary teeth, and it has a promising potential to become a replacement for FC in primary molars.